Opendata, web and dolomites

ScleroTest SIGNED

A rapid and cost-effective point-of-care diagnostic kit able to predict treatment response for appropriate Multiple Sclerosis management

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ScleroTest project word cloud

Explore the words cloud of the ScleroTest project. It provides you a very rough idea of what is the project "ScleroTest" about.

million    accumulated    fast    implantation    cure    alternatives    incidence    biomarker    diseases    routine    mainly    sclerosis    correct    02    ing    health    therapeutic    launch    young    magnetic    25    acute    quick    lack    predictive    personalized    bioithas    ms    chronic    autoimmune    profit    point    prevalence    care    people    18    nervous    competitive    added    worldwide    foresees    33    men    competition    lt    public    diagnostic    microbiota    absence    market    tool    commercial    issue    perform    predicting    sclerotest    treatment    performance    avenues    opportunity    company    15    rapid    properly    adults    annual    cagr    financial    neurologists    10    biotechnology    pcr    plan    feasibility    inflammatory    clinical    therapies    prompt    patient    technological    outcomes    virus    cheaper    successful    therapy    business    disease    accurate    58    ca    globally    2022    socioeconomic    analyzing    fruitful    resonance    profiling    biomarkers    substantial    2026    scalability    unmet    predict    plus    central    net    gut    finalize    multiple    poc    jc    immunomodulatory    secure    invasive    medicine    24    first    times    patients    savings    women   

Project "ScleroTest" data sheet

The following table provides information about the project.

Coordinator
BIOITHAS SL 

Organization address
address: C/ MAESTRO JOAQUIN ZAPATER 6
city: ONIL ALICANTE
postcode: 3430
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website https://www.bioithas.com/h2020-sclerotest-project/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOITHAS SL ES (ONIL ALICANTE) coordinator 50˙000.00

Map

 Project objective

Multiple sclerosis (MS) is the most common chronic inflammatory disease of the central nervous system currently affecting about 2.5 million people worldwide (mainly young adults, three times more women than men). There is no cure and therapies do not properly work in all patients. Personalized medicine is needed but we lack predictive biomarkers for treatment response to secure prompt and early treatment and the best clinical outcomes for each patient. Thus, MS represents a major public health issue with a substantial socioeconomic impact (€15.5 B annual costs in Europe). Bioithas is a biotechnology company in the field of health developing new diagnostic and therapeutic targets for autoimmune and inflammatory diseases. In response to the unmet need, it is focused on developing the first-ever gut microbiota based biomarker for predicting MS treatment response. ScleroTest, a quick point-of-care (PoC) diagnostic tool, will allow immunomodulatory profiling of patients to predict treatment response. It is a non-invasive, accurate (PCR performance), rapid (results in <24 h) and cost-competitive test (€25 test, ca. 58 % cheaper than magnetic resonance and JC virus alternatives). ScleroTest implantation in routine practice will face current MS management problems resulting on added value for patients, neurologists and health systems by allowing fast and correct therapy choice, better clinical outcomes and cost-savings. ScleroTest scalability will also open new avenues for personalized therapy in other diseases. Due to ScleroTest´s cost-competitive features plus the absence of real competition, the increasing MS prevalence and incidence globally and the growing PoC market (CAGR 10%, €33 B by 2022), Bioithas foresees ScleroTest as a fruitful business opportunity (accumulated net profit ca. €18.02 M, 2022-2026). To secure the successful market launch, we will perform a feasibility study analyzing technological, commercial and financial aspects to finalize our business plan.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SCLEROTEST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SCLEROTEST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More